Claims for Patent: 11,185,515

Summary for Patent: 11,185,515

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	16/952,759
Patent Claims:	1. A method of treating major depressive disorder, comprising: orally administering a dosage form to a human being suffering from major depressive disorder, wherein the dosage form is orally administered once a day or twice a day for at least 8 consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan or an intermediate metabolizer of dextromethorphan; wherein the dosage form comprises, as the only therapeutically active compounds, about 90 mg to about 140 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and about 40 mg to about 55 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; wherein orally administering the dosage form provides immediate release of dextromethorphan and sustained release of bupropion; and wherein orally administering the dosage form results in the human being experiencing a therapeutic effect and orally administering the dosage form is more effective in treating major depressive disorder than orally administering the same amount of the dextromethorphan alone for the same number of consecutive days. 2. The method of claim 1, wherein after orally administering the dosage form, the human being experiences an improvement in a depressive symptom as compared to baseline. 3. The method of claim 1, wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering a placebo. 4. The method of claim 1, wherein the dosage form is orally administered once daily. 5. The method of claim 1, wherein the dosage form is orally administered twice daily. 6. The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days. 7. The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days. 8. The method of claim 1, wherein the dosage form has a weight ratio of the dextromethorphan to the bupropion that is about 0.3 to about 0.5. 9. The method of claim 1, wherein the dosage form is orally administered once a day for 1 day and twice a day thereafter. 10. The method of claim 1, wherein the dosage form is orally administered once a day for 2 days and twice a day thereafter. 11. The method of claim 1, wherein the dosage form is orally administered once a day for 3 days and twice a day thereafter. 12. The method of claim 1, wherein the dosage form is orally administered once a day for 1, 2, 3, 4, 5, 6, or 7 days and twice a day thereafter. 13. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anxiety.